Literature DB >> 10766318

Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus.

A Gasbarrini1, V Ojetti, D Pitocco, A Armuzzi, N G Silveri, P Pola, G Ghirlanda, G Gasbarrini.   

Abstract

BACKGROUND: Patients with insulin-dependent diabetes mellitus (IDDM) are often affected by chronic infections; antibiotic absorption, however, may be influenced by the disease. H. pylori eradication appears to be reduced in IDDM patients. The aim of the study was to evaluate the efficacy of the most common H. pylori eradication regimens in a population of IDDM-infected patients.
METHODS: One hundred and seventy-two IDDM patients were evaluated. H. pylori infection was assessed through the 13C-urea breath test. Infected patients were randomly assigned to three different standard 7-day eradication regimens: 1) amoxicillin, clarithromycin, pantoprazole; 2) tinidazole, clarithromycin, ranitidine bismuth citrate; or 3) tinidazole, clarithromycin, pantoprazole. Patients in whom eradication was not successful in the first cycle were subsequently submitted to a 7-day therapy with tinidazole, tetracycline, bismuth, and pantoprazole.
RESULTS: Thirty-seven per cent of IDDM patients were infected. None of the triple therapies used provided an eradication higher than 62%. Conversely, the quadruple regimen was successful in 88% of the patients. Ten per cent of the subjects undergoing the triple therapies showed minor side effects, without significant differences among groups, whereas side effects occurred in 25% of the patients treated with the quadruple therapy (P < 0.05).
CONCLUSIONS: IDDM patients show a low H. pylori eradication rate with a standard triple therapy regardless of the regimen utilized, the dosage and/or the duration of the therapy used appearing not to be sufficient to eradicate the infection efficiently. The use of a quadruple regimen leads to the cure of a large percentage of the infected patients in whom the eradication was unsuccessful in the first therapy, although it is accompanied by a greater incidence of minor side effects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10766318     DOI: 10.1080/003655200750024119

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  11 in total

1.  Second-line rescue therapy of helicobacter pylori infection.

Authors:  Javier P Gisbert
Journal:  Therap Adv Gastroenterol       Date:  2009-11       Impact factor: 4.409

Review 2.  "Rescue" regimens after Helicobacter pylori treatment failure.

Authors:  Javier P Gisbert
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

3.  Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.

Authors:  J P Gisbert; A Perez-Aisa; L Rodrigo; J Molina-Infante; I Modolell; F Bermejo; M Castro-Fernández; R Antón; B Sacristán; A Cosme; J Barrio; Y Harb; M Gonzalez-Barcenas; M Fernandez-Bermejo; A Algaba; A C Marín; A G McNicholl
Journal:  Dig Dis Sci       Date:  2013-10-15       Impact factor: 3.199

4.  Treatment of Helicobacter pylori Eradication Failures.

Authors:  Javier P. Gisbert; José María Pajares
Journal:  Curr Treat Options Gastroenterol       Date:  2003-04

5.  Helicobacter pylori infection is not associated with delayed gastric emptying or upper gastrointestinal symptoms in diabetes mellitus.

Authors:  Karen L Jones; Judith M Wishart; Melanie Berry; Antonietta Russo; Harry Hua-Xiang Xia; Nicholas J Talley; Michael Horowitz
Journal:  Dig Dis Sci       Date:  2002-04       Impact factor: 3.199

6.  Type 2 diabetes mellitus affects eradication rate of Helicobacter pylori.

Authors:  Mehmet Sargýn; Oya Uygur-Bayramicli; Haluk Sargýn; Ekrem Orbay; Dilek Yavuzer; Ali Yayla
Journal:  World J Gastroenterol       Date:  2003-05       Impact factor: 5.742

7.  The eradication of Helicobacter pylori is affected by body mass index (BMI).

Authors:  Mohamed Abdullahi; Bruno Annibale; Danila Capoccia; Roberto Tari; Edith Lahner; John Osborn; Frida Leonetti; Carola Severi
Journal:  Obes Surg       Date:  2008-04-29       Impact factor: 4.129

Review 8.  Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis.

Authors:  Alexander C Ford; Peter Malfertheiner; Monique Giguere; Jose Santana; Mostafizur Khan; Paul Moayyedi
Journal:  World J Gastroenterol       Date:  2008-12-28       Impact factor: 5.742

Review 9.  Is Helicobacter pylori infection associated with glycemic control in diabetics?

Authors:  Yi-Ning Dai; Wei-Lai Yu; Hua-Tuo Zhu; Jie-Xia Ding; Chao-Hui Yu; You-Ming Li
Journal:  World J Gastroenterol       Date:  2015-05-07       Impact factor: 5.742

Review 10.  Helicobacter pylori infection and endocrine disorders: is there a link?

Authors:  Konstantinos X Papamichael; Garyphallia Papaioannou; Helen Karga; Anastasios Roussos; Gerassimos J Mantzaris
Journal:  World J Gastroenterol       Date:  2009-06-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.